Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04477954
Recruitment Status : Recruiting
First Posted : July 20, 2020
Last Update Posted : August 19, 2020
Sponsor:
Collaborators:
Hospital de Infecciosas Francisco Javier Muniz
Hospital General de Agudos D. F. Santojanni
Hospital Central de San Isidro Dr. Melchor Angel Posse
Information provided by (Responsible Party):
Mariana Cannellotto, Asociación Argentina de Medicina Hiperbárica e Investigación

Brief Summary:
The severity of COVID-19 is related to the level of hypoxemia, respiratory failure, how long it lasts and how refractory it is at increasing concentrations of inspired oxygen. The inability to perform hematosis due to edema that occurs from acute inflammation could be attenuated by the administration of hyperbaric oxygen (HBO). Recently, it has been reported benefits in this matter in patients with SARS-CoV-2 hypoxemic pneumonia in China; where the administration of repeated HBO sessions decreased the need for mechanical ventilation (MV) in patients admitted to the Intensive Care Unit due to COVID-19. Hyperbaric oxygen is capable of increasing drastically the amount of dissolved oxygen in the blood and maintain an adequate supply oxygen to the tissues. In addition to this, it can influence immune processes, both humoral and cellular, allowing to reduce the intensity of the response inflammatory and stimulate antioxidant defenses. HBO is considered safe and it has very few adverse events, it is a procedure approved by our authorities regulatory for several years. In the current context of the pandemic by COVID-19 and worldwide reports of mortality associated with severe cases of respiratory failure, it is essential to propose therapeutical strategies to limit or decrease respiratory compromise of severe stages by COVID-19. That is why, it is proposed to carry out this research to assess whether HBO treatment can improve the evolution of patients with COVID-19 severe hypoxemia.

Condition or disease Intervention/treatment Phase
Covid19 Combination Product: Hyperbaric Oxygen Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia
Actual Study Start Date : July 6, 2020
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 30, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Oxygen Therapy

Arm Intervention/treatment
Experimental: Experimental HBOT
Treatment (device). Patients will receive 90 minutes of hyperbaric oxygen at 1,45 ATA in a Revitalair430 hyperbaric chamber, and then they will continue with standard care and normobaric oxygen.
Combination Product: Hyperbaric Oxygen
Hyperbaric oxygen therapy (HBOT): inhalation of pressurized oxygen through a hyperbaric chamber (Revitalair430)
Other Name: HBOT

No Intervention: Standard care



Primary Outcome Measures :
  1. Time to normalize the oxygen requirement (oxygen dependence) [ Time Frame: 15-30 days. ]
    Time to normalize the oxygen requirement: Allowing a pulse oximetry value in ambient air greater than or equal 93% and/or arterial blood gas with PaO2 value greater than 60 mmHg in ambient air.


Secondary Outcome Measures :
  1. Need for Invasive Mechanical Ventilation (IMV) and / or Respiratory Distress Syndrome Acute (ARDS) [ Time Frame: 30 days ]
    Number of patients who required IMV after being enrolled

  2. Development of Acute Respiratory Distress Syndrome (ARDS) [ Time Frame: 30 days ]
    Number of patients who required IMV and / or had a diagnosis of ARDS after being enrolled.

  3. 30-day mortality [ Time Frame: 30 days ]
    Number of patients who died in that period since enrollment

  4. Hypotension with vasopressor requirement [ Time Frame: 30 days ]
    Number of patients with hypotension who were administered vasopressors in this period

  5. Mortality [ Time Frame: 45 days / 60 days / 90 days and 180 days ]
    Number of patients who died in that period since enrollment.


Other Outcome Measures:
  1. Adverse events [ Time Frame: 4 hours finished session ]
    Number of adverse events reported related to the device (Revitalair 430 hyperbaric chamber): otalgias, ear obstruction, barotrauma, significant and constant changes in blood pressure, heart rate and others



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years, all sexes.
  • No previous hospitalizations in the last 6 months.
  • Positive diagnostic test for COVID-19 according to the guidelines of the Argetine Ministry of Health at the time of enrollment.
  • Patient in Intensive Care Unit with oxygen need: Need for continuous supply of oxygen to maintain saturation by oximetry pulse (SpO2) greater than or equal to 93% or arterial gas with PaO2 value greater than 60 mmHg

Exclusion Criteria:

  • 18 years of age.
  • Person unable to give consent.
  • Person who refuses to participate.
  • Pregnancy and lactation
  • Participating in other study
  • Requirement for mechanical ventilation.
  • Inability to maintain prolonged sitting position (at least 2 hours)
  • Subject with contraindications to HBOT (pulmonary shock, bullae, emphysema or untreated pneumothorax, severe seizures, uncontrolled hypertension, chronic obstructive disease of grade III or IV).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04477954


Contacts
Layout table for location contacts
Contact: Mariana Cannellotto, MD +5491165103300 mariana.cannellotto@aamhei.org
Contact: Fabrizio Verdini, MD +5491127719470 fabrizio.verdini@aamhei.org

Locations
Layout table for location information
Argentina
Hospital Central de San Isidro Dr. Angel Melchor Posse Recruiting
San Isidro, Buenos Aires, Argentina, 1641
Contact: Mariana Cannellotto, MD    01147025444    mariana.cannellotto@aamhei.org   
Principal Investigator: Ramiro Larrea, MD         
Sub-Investigator: Mariela Alejandra Mansur, MD         
Sub-Investigator: Daniela Mariel Brito, MD         
Sub-Investigator: Maria Estela Ramirez, MD         
Sub-Investigator: Carlos Alejandro Marquez, MD         
Hospital de Infecciosas F. J. Muñiz Recruiting
Ciudad Autonoma de Buenos AIres, Caba, Argentina, 1282
Contact: Mariana Cannellotto, MD    01147025444    mariana.cannellotto@aamhei.org   
Principal Investigator: Eleonora Cunto, MD         
Sub-Investigator: Viviana Chediack, MD         
Sub-Investigator: Cecilia Dominguez, MD         
Hospital General de Agudos D.F Santojanni Recruiting
Ciudad Autonoma de Buenos AIres, Caba, Argentina, 1408
Contact: Mariana Cannellotto, MD    01147025444    mariana.cannellotto@aamhei.org   
Principal Investigator: Guillermo Keller, MD         
Sponsors and Collaborators
Asociación Argentina de Medicina Hiperbárica e Investigación
Hospital de Infecciosas Francisco Javier Muniz
Hospital General de Agudos D. F. Santojanni
Hospital Central de San Isidro Dr. Melchor Angel Posse
Investigators
Layout table for investigator information
Study Chair: Mariana Cannellotto, MD Asociación Argentina de Medicina Hiperbárica e Investigación
Principal Investigator: Mariano Duarte, PhD Asociación Argentina de Medicina Hiperbárica e Investigación
Principal Investigator: Liliana Jorda-Vargas Asociación Argentina de Medicina Hiperbárica e Investigación
Principal Investigator: Fabrizio Verdini, MD Asociación Argentina de Medicina Hiperbárica e Investigación
Layout table for additonal information
Responsible Party: Mariana Cannellotto, President, Asociación Argentina de Medicina Hiperbárica e Investigación
ClinicalTrials.gov Identifier: NCT04477954    
Other Study ID Numbers: AAMHEI2020-1
First Posted: July 20, 2020    Key Record Dates
Last Update Posted: August 19, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Mariana Cannellotto, Asociación Argentina de Medicina Hiperbárica e Investigación:
Hyperbaric Oxygen
Covid-19
Hypoxemia
Sars-CoV2
Hyperbaric Chamber
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypoxia
Signs and Symptoms, Respiratory